<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Prevention of type 2 diabetes mellitus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Prevention of type 2 diabetes mellitus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Prevention of type 2 diabetes mellitus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            R Paul Robertson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Type 2 diabetes mellitus is characterized by hyperglycemia, insulin resistance, and impairment in insulin secretion. Although the lifetime risk of type 2 diabetes is high, our ability to predict and prevent type 2 diabetes in the general population is challenging. However, individuals at high risk, including those with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), obesity, close relatives with type 2 diabetes, or who are members of certain ethnic groups (Asian, Hispanic, African American), are appropriate candidates for preventive interventions [
         <a href="#rid1">
          1
         </a>
         ]. Moreover, genetic risk factors for type 2 diabetes have increasingly been identified, and polygenic risk scores may enhance the traditional demographic and clinical risk factor stratification in the future [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The prevention of type 2 diabetes mellitus will be reviewed here. The prevalence, risk factors, and screening for type 2 diabetes are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">
          "Type 2 diabetes mellitus: Prevalence and risk factors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2117782980">
         <span class="h1">
          GOALS OF DIABETES PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of diabetes prevention include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preventing or delaying the onset of diabetes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preserving beta cell function
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preventing or delaying microvascular and cardiovascular complications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ultimately, reducing costs of diabetes care
        </p>
        <p>
        </p>
        <p>
         As a therapeutic target, preservation of beta cell function may be particularly important as beta cell failure largely underlies the transition from prediabetic states to diabetes (as well as worsening of glycemia once diabetes has developed).
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          OUR APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach outlined below is largely consistent with the American Diabetes Association (ADA) guidelines [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2746909570">
         <span class="h2">
          Identify individuals for preventive measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         In order to identify individuals who are appropriate candidates for preventive interventions, we measure glycated hemoglobin (A1C) or fasting plasma glucose (FPG) in adults ≥35 years, in women with a history of gestational diabetes, and in adults of any age with body mass index (BMI) ≥25 kg/m
         <sup>
          2
         </sup>
         (≥23 kg/m
         <sup>
          2
         </sup>
         in Asian Americans) who have one or more additional risk factors for diabetes  (
         <a class="graphic graphic_table graphicRef122948" href="/z/d/graphic/122948.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of diabetes mellitus in a first-degree relative
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High risk race/ethnicity (eg, African, Latino, Asian, or Native American descent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedentary lifestyle
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyslipidemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of cardiovascular disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polycystic ovary syndrome (women)
        </p>
        <p>
        </p>
        <p>
         Although oral glucose tolerance testing (OGTT) has been used to identify people at high risk to develop type 2 diabetes in almost all of the clinical trials, in practice, we usually use the A1C or FPG as more practical (and as recommended for diagnosis of diabetes by the ADA). (See
         <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">
          "Type 2 diabetes mellitus: Prevalence and risk factors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FPG ≥126 mg/dL or A1C ≥6.5 percent
         </strong>
         – If FPG is ≥126 mg/dL (7 mmol/L) or A1C ≥6.5 percent (48 mmol/mol), the individual has met the criteria for the diagnosis of diabetes mellitus. The initial test should be repeated to confirm the diagnosis  (
         <a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">
          table 2
         </a>
         ). Appropriate management of patients with diabetes is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FPG 100 to 125 mg/dL or A1C 5.7 to 6.4 percent
         </strong>
         – If the FPG or A1C value is abnormal, the initial test should be repeated to confirm abnormal glucose metabolism  (
         <a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">
          table 3
         </a>
         ). For patients with FPG 100 to 125 mg/dL, called impaired fasting glucose (IFG), or A1C of 5.7 to 6.4 percent (39 to 46 mmol/mol), we promote lifestyle changes (healthy diet, exercise) (see
         <a class="local">
          'Lifestyle modification'
         </a>
         below). We repeat testing annually.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the risk for developing diabetes follows a continuum across all levels of subdiabetic, abnormal glucose metabolism, when classified categorically, people with IFG, impaired glucose tolerance (IGT), or an A1C level of 5.7 to 6.4 percent (39 to 46 mmol/mol) are at increased risk of developing type 2 diabetes compared with those with lower levels  (
         <a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">
          table 3
         </a>
         ). Individuals with additional diabetes clinical risk factors, including obesity and family history of diabetes, are even more likely to develop diabetes (see
         <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">
          "Type 2 diabetes mellitus: Prevalence and risk factors"
         </a>
         ). Lifestyle changes can be endorsed for patients at all risk levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FPG &lt;100 mg/dL or A1C &lt;5.7 percent
         </strong>
         – If glycemic indices are normal (FPG is &lt;100 mg/dL [5.6 mmol/L] or A1C &lt;5.7 percent [39 mmol/mol]), we retest (A1C or FPG) in high-risk individuals at two- to three-year intervals (see
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus", section on 'A suggested approach'
         </a>
         ). We promote lifestyle changes (healthy diet and regular exercise) to all patients.
        </p>
        <p>
        </p>
        <p>
         The 75 gram OGTT is not often used clinically other than during pregnancy, because of inconvenience. For patients with IGT, defined as a two-hour glucose 140 to 199 mg/dL (7.8 mmol/L to 11.0 mmol/L) after a 75 gram OGTT, confirmation with a repeat test should be performed with subsequent annual testing with one of the more convenient measures of glycemia.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Lifestyle modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with IGT, IFG, or an A1C of 5.7 to 6.4 percent (39 to 46 mmol/mol)  (
         <a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">
          table 3
         </a>
         ) should be provided with a comprehensive lifestyle modification program that includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Behavior modification
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical activity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smoking cessation
        </p>
        <p>
        </p>
        <p>
         The goal of the lifestyle intervention is weight loss with return to normal glycemia. Regular reinforcement of the program is important for successful compliance.
        </p>
        <p>
         Although insulin resistance and impaired insulin secretion in type 2 diabetes have a substantial genetic component, they can also be influenced, both positively and negatively, by environmental and behavioral factors. Changes in lifestyle, including diet modification, weight loss, and exercise, slow progression of IGT to overt diabetes [
         <a href="#rid4">
          4-7
         </a>
         ]. The beneficial effects of such intervention appear to continue after the original intervention [
         <a href="#rid8">
          8-12
         </a>
         ]. Except for one controlled clinical trial with 30 years of total follow-up in a Chinese population that demonstrated reductions in cardiovascular disease (CVD) and total mortality, neither lifestyle changes nor pharmacologic therapy have been shown to reduce morbidity or mortality in patients at high risk for developing diabetes [
         <a href="#rid13">
          13,14
         </a>
         ]. Lifestyle changes are generally beneficial and do not have adverse effects. (See
         <a class="local">
          'Lifestyle intervention'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1847051241">
         <span class="h2">
          Assess response to lifestyle intervention
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with abnormal glucose metabolism (FPG 100 to 125 mg/dL or A1C 5.7 to 6.4 percent) participating in a lifestyle modification program, we reassess fasting glucose or A1C annually.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management if lifestyle intervention unsuccessful
         </strong>
         – For select patients (age &lt;60 years and/or BMI ≥35 kg/m
         <sup>
          2
         </sup>
         , history of gestational diabetes) in whom lifestyle interventions fail to improve glycemic indices, we suggest
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for diabetes prevention  (
         <a class="graphic graphic_table graphicRef67073" href="/z/d/graphic/67073.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Metformin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This suggestion is based upon the findings of the Diabetes Prevention Program (DPP), in which
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         was particularly effective for diabetes prevention in those at highest risk for developing diabetes (individuals who were younger, with class II obesity [BMI &gt;35 kg/m
         <sup>
          2
         </sup>
         ], or with a history of gestational diabetes). In older individuals (≥60 years of age at baseline), the lifestyle intervention was particularly effective (72 percent reduction in diabetes compared with placebo), while metformin was relatively less effective. (See
         <a class="local">
          'Diabetes Prevention Program'
         </a>
         below and
         <a class="local">
          'Pharmacologic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients treated with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         require at least annual monitoring (A1C or FPG) for the development of diabetes. (See
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who are not treated with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         should also be followed, with repeat examination and annual measurements of FPG or A1C, as well as serum lipids. If FPG increases to ≥126 mg/dL (7 mmol/L) or A1C ≥6.5 percent (48 mmol/mol), appropriate management of diabetes is necessary. (See
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Diagnostic criteria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management if lifestyle intervention successful
         </strong>
         – Patients who improve or maintain their glycemic indices with lifestyle interventions should continue diet and exercise with repeat examination and measurements of fasting blood glucose or A1C and serum lipids on an annual basis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          LIFESTYLE INTERVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         We promote lifestyle changes (healthy diet and regular exercise) to all patients.
        </p>
        <p class="headingAnchor" id="H3792686380">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lifestyle intervention (combined diet and exercise aimed at weight loss and increasing activity levels) can improve glucose tolerance and prevent progression from impaired glucose tolerance (IGT) to type 2 diabetes, as illustrated by meta-analyses of trials comparing exercise plus diet with standard therapy (risk ratio [RR] with intervention compared with control 0.59, 95% CI 0.51-0.66) [
         <a href="#rid4">
          4-7,15
         </a>
         ]. The beneficial effect of the original lifestyle intervention appears to persist for years after the end of the study [
         <a href="#rid8">
          8-12
         </a>
         ].
        </p>
        <p>
         Some of the individual trials  (
         <a class="graphic graphic_table graphicRef113534" href="/z/d/graphic/113534.html" rel="external">
          table 5
         </a>
         ) in the meta-analyses are described below.
        </p>
        <p>
         The glycemic benefit of sustained weight reduction in patients already diagnosed with type 2 diabetes is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Intensive lifestyle modification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Finnish Diabetes Prevention Study
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Finnish Diabetes Prevention Study randomly assigned 522 middle-aged patients with IGT (mean age 55 years, mean body mass index [BMI] 33.2 kg/m
         <sup>
          2
         </sup>
         ) to a weight reduction and exercise program or a control group [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mean weight loss in the intervention group was 3.5 kg at the end of two years compared with 0.8 kg in the control group. At the end of four years, the cumulative incidence of diabetes was significantly lower in the intervention group (11 versus 23 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The effect of the original lifestyle intervention appears to persist for at least three years after the end of the study. Patients who were diabetes free at four years were followed for an additional three years [
         <a href="#rid8">
          8
         </a>
         ]. No further lifestyle intervention was provided through the study during the extended follow-up. The reduction in diabetes incidence associated with the original intensive lifestyle group continued, although not as powerfully during the three-year follow-up (58 percent reduction during the trial; 36 percent reduction during the three-year follow-up). Over the extended seven-year follow-up, comparing intervention and control groups, the hazard ratio (HR) for diabetes was 0.57 (95% CI 0.43-0.76), with cumulative incidence of diabetes 23 versus 38 percent at the end of year 6 (43 percent reduction over the entire period).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Diabetes Prevention Program
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of a second trial, the Diabetes Prevention Program (DPP), were similar [
         <a href="#rid17">
          17
         </a>
         ]. In this trial, 3234 people with obesity (average BMI 34 kg/m
         <sup>
          2
         </sup>
         ) aged 25 to 85 years (average 51 years) at high risk for diabetes (based on BMI ≥24 kg/m
         <sup>
          2
         </sup>
         , and fasting and two-hour plasma glucose concentrations of 96 to 125 mg/dL [5.3 to 6.9 mmol/L] and 140 to 199 mg/dL [7.8 to 11.1 mmol/L], respectively) were randomly assigned to one of the following groups:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intensive lifestyle changes with the aim of reducing weight by 7 percent through a behavioral modification program aimed at a low-fat diet and exercise for 150 minutes per week. Details of the lifestyle intervention have been published [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         (850 mg twice daily) plus information on diet and exercise.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placebo plus information on diet and exercise.
        </p>
        <p>
        </p>
        <p>
         The study was terminated one year ahead of schedule when the independent data safety monitoring board determined that the study hypotheses had been answered: at an average follow-up of three years, fewer patients in the intensive lifestyle group developed diabetes, as diagnosed by fasting plasma glucose (FPG) and two-hour post-load glucose concentrations (14 versus 22 and 29 percent in the
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         and placebo groups, respectively). The intensive lifestyle and metformin interventions reduced the cumulative incidence of diabetes by 58 and 31 percent, respectively [
         <a href="#rid17">
          17
         </a>
         ]. Lifestyle intervention was effective in males and females in all age groups, in all ethnic groups, and across all risk levels [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The diet and exercise group lost an average of 15 pounds (6.8 kg; 7 percent) of weight in the first year, most of which was sustained for the duration of the study. An analysis of patients in the intensive lifestyle group found that, within the three components of the intervention (weight loss, diet change, and exercise), diabetes prevention correlated most strongly with weight loss; there was a 16 percent reduction in diabetes risk for every kilogram reduction in weight [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History of gestational diabetes
         </strong>
         – In contrast to the findings in the entire DPP cohort (lifestyle intervention more effective than
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         therapy), metformin and lifestyle intervention were similarly effective in reducing the incidence of diabetes in women with a history of gestational diabetes [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a preplanned subset analysis of women with a history of gestational diabetes and IGT, the incidence of diabetes was reduced by 50 and 53 percent in subjects assigned to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         and lifestyle intervention, respectively, compared with placebo. In parous women with IGT and without a history of gestational diabetes, risk reductions with metformin and lifestyle (compared with placebo) were 14 and 49 percent, respectively. The discrepancy is due, in part, to the higher cumulative incidence of diabetes during the three-year trial in women assigned to placebo with versus without gestational diabetes (38.4 versus 25.7 percent) and in part due to the inability of women with a history of gestational diabetes randomly assigned to intensive lifestyle intervention to sustain physical activity and maintain weight loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes defined by A1C
         </strong>
         –
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         and lifestyle intervention were similarly effective in reducing the incidence of diabetes when diabetes was defined by A1C criteria (≥6.5 percent) rather than FPG or post-load glucose concentrations [
         <a href="#rid22">
          22
         </a>
         ]. Although A1C was measured at baseline and throughout the DPP, it was not used for study eligibility or outcomes. In a subsequent analysis of data from the DPP, 2765 patients without diabetes at baseline according to FPG (&lt;126 mg/dL [7.0 mmol/L]), two-hour post-load glucose (&lt;200 mg/dL [11.1 mmol/L]), and A1C criteria (&lt;6.5 percent) were included in the analysis [
         <a href="#rid22">
          22
         </a>
         ]. The reduction in the incidence of diabetes defined by A1C ≥6.5 percent was similar in the metformin and lifestyle intervention groups (reduced by 44 and 49 percent, respectively [compared with reductions of 31 and 58 percent in diabetes diagnosed by FPG and two-hour post-load glucose criteria]). The long-term health (microvascular disease, cardiovascular risk factors) implications of the interventions and the diagnostic differences in defining them are uncertain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Persistent benefit after intervention
         </strong>
         – In a follow-up observational study, the Diabetes Prevention Program Outcomes (DPPOS), the benefit of the lifestyle intervention persisted over 10 years. In this study, 85 percent of patients originally enrolled in DPP joined the long-term follow-up and were offered group-implemented lifestyle intervention [
         <a href="#rid9">
          9
         </a>
         ]. Patients originally assigned to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         continued receiving it (unblinded). During a cumulative 10 years of follow-up, the incidence of diabetes in the lifestyle and metformin groups was significantly reduced by 34 and 18 percent, respectively, compared with placebo. In a subsequent analysis of participants with IGT who completed the DPP without developing diabetes, participants who reverted to normal glucose tolerance at least once during the DPP had a lower risk of diabetes during DPPOS than those who consistently had prediabetes (HR 0.44, 95% CI 0.37-0.55) [
         <a href="#rid10">
          10
         </a>
         ]. This finding was unaffected by previous group assignment and suggests that reversion to normal glucose tolerance, even if brief, is associated with an enduring reduction in the risk of developing diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Follow-up after 15 years showed a continued benefit in the original lifestyle intervention and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         groups with long-term reductions in diabetes development of 27 and 18 percent, respectively, compared with the original placebo group (cumulative incidence of diabetes 55, 56, and 62 percent in the lifestyle, metformin, and placebo groups, respectively) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Both lifestyle interventions and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         therapy are effective prevention strategies (with similar efficacy in the subset of women with a history of gestational diabetes and when diabetes is defined by A1C ≥6.5 percent). In older individuals (≥60 years of age at baseline), the lifestyle intervention was particularly effective (72 percent reduction in diabetes compared with placebo), while metformin was relatively less effective. Conversely, metformin was particularly effective in individuals who were younger (&lt;60 years of age), with class II obesity (BMI &gt;35 kg/m
         <sup>
          2
         </sup>
         ), and at highest risk for developing diabetes.
        </p>
        <p>
         A cost-effectiveness analysis using data from the DPP (three years) and the DPPOS (seven years) showed that lifestyle intervention was cost effective compared with placebo [
         <a href="#rid24">
          24
         </a>
         ]. Moreover,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         was actually cost-saving. Numerous lifestyle intervention programs based upon the DPP, including one implemented through YMCAs and numerous state-wide programs, have been successfully initiated nationwide and demonstrated comparable weight loss results as in the original DPP. Long-term compliance with previous dietary interventions has been poor, and new behavioral strategies, like those used in the DPP, need to be identified to promote cost-effective and long-term weight loss. (See
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2741514022">
         <span class="h2">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there is no one exercise prescription for all individuals, adults at high risk for diabetes are encouraged to perform 30 to 60 minutes of moderate-intensity aerobic activity on most days of the week (at least 150 minutes of moderate-intensity aerobic exercise per week).
        </p>
        <p>
         The benefit of exercise in preventing diabetes has been demonstrated in numerous studies [
         <a href="#rid17">
          17,25-31
         </a>
         ]. A meta-analysis of 28 prospective cohort studies of physical activity and type 2 diabetes reported a lower risk of developing diabetes with 150 min/week of moderate physical activity, including brisk walking, compared with being sedentary (relative risk 0.74, 95% CI 0.69-0.80) [
         <a href="#rid32">
          32
         </a>
         ]. Additional benefits were seen with higher levels of activity (300 min/week, relative risk 0.64, 95% CI 0.56-0.73). The changes in glucose metabolism that can occur with exercise are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1777.html" rel="external">
          "Exercise guidance in adults with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         In a subsequent prospective cohort study in men, either weight training or aerobic exercise for at least 150 minutes per week was associated with a lower risk of developing type 2 diabetes than no physical activity (relative risk 0.66, 95% CI 0.46-0.93 for weight training and relative risk 0.48, 95% CI 0.42-0.55 for aerobic exercise) [
         <a href="#rid33">
          33
         </a>
         ]. Men who combined aerobic and weight training exercise had the greatest reduction in diabetes risk.
        </p>
        <p class="headingAnchor" id="H1942566424">
         <span class="h2">
          Diet
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest choosing a dietary pattern of healthful foods, such as the Dietary Approaches to Stop Hypertension (DASH) or Mediterranean-style diet, rather than focusing on a specific nutrient. This approach allows greater flexibility and personal preference in diet and may improve long-term adherence [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         There are few trials examining the effects of diet alone (without weight loss) for the prevention of diabetes. In one trial, a Mediterranean diet appeared to reduce the incidence of diabetes independent of weight loss [
         <a href="#rid35">
          35-37
         </a>
         ]. This trial, which included 7447 adults, examined the effects of two different Mediterranean diets (one supplemented with extra virgin olive oil, the other with mixed nuts) versus a low-fat control diet on cardiovascular outcomes in adults at high risk for cardiovascular disease (CVD; eg, type 2 diabetes or three or more cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, BMI ≥25 kg/m
         <sup>
          2
         </sup>
         , or family history of premature CVD) [
         <a href="#rid38">
          38
         </a>
         ]. The incidence of diabetes could be ascertained (FPG or two-hour oral glucose tolerance test [OGTT] during follow-up, and if results consistent with diabetes, a repeat measurement within three months) in a subgroup of 3541 individuals without diabetes at baseline [
         <a href="#rid36">
          36,39
         </a>
         ]. After a median follow-up of four years, there was a decreased risk of developing diabetes in the groups assigned to the Mediterranean diets (3.8, 3.4, and 4.4 percent developed diabetes in the groups assigned to the Mediterranean diet supplemented with olive oil, Mediterranean diet supplemented with nuts, and the control diet, respectively [HRs 0.69, 95% CI 0.53-0.91 and 0.72, 95% CI 0.54-0.95 for the olive oil and nut groups, respectively, compared with controls]) [
         <a href="#rid39">
          39
         </a>
         ]. Changes in weight and physical activity did not differ among the three groups.
        </p>
        <p>
         Although these results suggest that a Mediterranean diet reduces the incidence of diabetes independent of weight loss, they should be interpreted with caution, as this was an exploratory analysis of a trial in which randomization was not stratified by diabetes status and which was stopped early due to benefit. These limitations combined with the small number of events (273) and the greater losses to follow-up in the control group may have resulted in overestimation of benefit. In addition, it remains uncertain which components of the Mediterranean diet offer the protective benefit or if the benefits result from an aggregation of effects. There is no single definition of a Mediterranean diet, but such diets are typically high in fruits, vegetables, whole grains, beans, nuts, and seeds; include olive oil as an important source of monounsaturated fat; and allow low to moderate wine consumption. There are typically low to moderate amounts of fish, poultry, and dairy products, with little red meat (see
         <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">
          "Healthy diet in adults", section on 'Mediterranean diet'
         </a>
         ). Randomized trials of Mediterranean diets with diabetes as a primary endpoint are needed before they can be recommended for the prevention of diabetes.
        </p>
        <p>
         In another trial, the Women's Health Initiative Dietary Modification Trial (WHI DMT), a low-fat diet (20 percent of caloric intake) did not reduce the incidence of diabetes compared with a usual diet (approximately 7 percent in each group) [
         <a href="#rid40">
          40
         </a>
         ]. The difference in weight between the two groups was less than 2 kg. These results, which suffer from the absence of uniform glucose testing in the study, suggest that in average-risk women, a low-fat diet without weight reduction does not prevent diabetes.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several large, prospective, observational studies have shown that cigarette smoking increases the risk of type 2 diabetes. The effect of smoking cessation on diabetes risk is variable and may depend upon individual patient factors. Smoking cessation may reduce diabetes risk by reducing systemic inflammation. On the other hand, smoking cessation is often associated with weight gain, which will increase the risk of diabetes. This topic is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">
          "Type 2 diabetes mellitus: Prevalence and risk factors", section on 'Smoking'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          PHARMACOLOGIC THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug therapy may be helpful in preventing type 2 diabetes in high-risk patients for whom lifestyle interventions fail or are not sustainable. However, the impact on cardiovascular disease (CVD) risk factors is less clear and varies with the individual drug. In addition, the long-term effects on cardiovascular events are unknown [
         <a href="#rid41">
          41,42
         </a>
         ]. Furthermore, the long-term benefits and cost effectiveness of early pharmacologic treatment versus withholding treatment until diabetes develops are unproven [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Lifestyle changes, which are at least as effective and may be cheaper than most drugs used in prevention trials, are considered first-line preventive therapy [
         <a href="#rid44">
          44
         </a>
         ]. Although lifestyle changes have not been shown to reduce morbidity or mortality thus far, lifestyle changes are generally beneficial and do not have adverse effects. (See
         <a class="local">
          'Our approach'
         </a>
         above and
         <a class="local">
          'Lifestyle intervention'
         </a>
         above and
         <a class="local">
          'Guidelines'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3027901413">
         <span class="h2">
          Choice of drug therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For selected patients (age &lt;60 years and/or body mass index [BMI] ≥35 kg/m
         <sup>
          2
         </sup>
         , women with a history of gestational diabetes) with impaired glucose tolerance (IGT), impaired fasting glucose (IFG), or A1C of 5.7 to 6.4 percent (39 to 46 mmol/mol), in whom lifestyle interventions fail to improve glycemic indices, we suggest
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for diabetes prevention (850 mg once daily for one month; if tolerating, increase to 850 mg twice daily)  (
         <a class="graphic graphic_table graphicRef67073" href="/z/d/graphic/67073.html" rel="external">
          table 4
         </a>
         ). Metformin has been approved for prevention in several countries internationally but remains off-label for prevention in the United States. (See
         <a class="local">
          'Metformin'
         </a>
         below.)
        </p>
        <p>
         This is in agreement with the American Diabetes Association (ADA) guidelines [
         <a href="#rid3">
          3,45
         </a>
         ]. (See
         <a class="local">
          'Guidelines'
         </a>
         below.)
        </p>
        <p>
         For individuals with IFG, IGT, or A1C of 5.7 to 6.4 percent (39 to 46 mmol/mol) who are candidates for obesity pharmacotherapy,
         <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">
          semaglutide
         </a>
         used for the treatment of obesity may help reduce the risk of progression to type 2 diabetes. (See
         <a class="local">
          'Semaglutide'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy", section on 'Subcutaneous semaglutide'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Metformin
         </span>
         <span class="headingEndMark">
          —
         </span>
         A meta-analysis of randomized trials of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for the prevention of diabetes in high-risk individuals showed that metformin decreased new-onset diabetes compared with standard diet and exercise, with or without placebo (141 versus 281 per 1000, risk ratio [RR] 0.5, 95% CI 0.38-0.65) [
         <a href="#rid42">
          42
         </a>
         ]. Metformin did not reduce the development of type 2 diabetes compared with
         <strong>
          intensive
         </strong>
         diet and exercise (133 versus 167 per 1000 in the intensive intervention group, RR 0.80, 95% CI 0.47-1.37). There were insufficient data to address patient important outcomes, such as micro- and macrovascular outcomes and mortality.
        </p>
        <p>
         In the largest trial in the meta-analysis, the Diabetes Prevention Program (DPP) described above (see
         <a class="local">
          'Diabetes Prevention Program'
         </a>
         above),
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         reduced the rate of progression to diabetes compared with placebo (22 versus 29 percent at an average follow-up of three years [in the intensive lifestyle arm, the incidence of diabetes was 14 percent]) [
         <a href="#rid17">
          17
         </a>
         ]. Metformin was effective in males and females and in all ethnic groups but was relatively ineffective in older patients and in those who were less overweight. Metformin was most effective in reducing the risk of diabetes in younger people with obesity, and particularly in women with a history of gestational diabetes [
         <a href="#rid21">
          21
         </a>
         ]. Metformin is relatively inexpensive and has no long-term, serious side effects. (See
         <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">
          "Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         There has been concern that the diabetes prevention benefit of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         might represent a delaying of the development of diabetes rather than true prevention since follow-up oral glucose tolerance testing (OGTT) in most studies was done while patients were still taking the medication. In one follow-up study of 1274 subjects in the DPP metformin group (who had not developed diabetes), follow-up OGTTs after stopping metformin (on average 11 days) showed that approximately 75 percent of the metformin benefit persisted [
         <a href="#rid46">
          46
         </a>
         ]. Although the authors suggested that this finding is consistent with prevention, longer drug-free trials are needed to firmly draw this conclusion.
        </p>
        <p>
         Patients treated with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         require at least annual monitoring (A1C or fasting glucose).
        </p>
        <p class="headingAnchor" id="H944738015">
         <span class="h3">
          Semaglutide
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with prediabetes and overweight or obesity,
         <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">
          semaglutide
         </a>
         may help delay or prevent diabetes onset when used as obesity pharmacotherapy. In a prespecified secondary analysis from the Semaglutide Treatment Effect in People with obesity (STEP) 1 trial, adults with prediabetes (mean BMI approximately 39 kg/m
         <sup>
          2
         </sup>
         , mean A1C approximately 5.9 percent) who were randomly assigned to once-weekly semaglutide 2.4 mg for 68 weeks had a lower frequency of progression to type 2 diabetes than those who received placebo (0.5 versus 3 percent) [
         <a href="#rid47">
          47
         </a>
         ]. Participants in both groups underwent concurrent lifestyle intervention. The STEP trials are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy", section on 'Subcutaneous semaglutide'
         </a>
         .)
        </p>
        <p>
         The extent to which these effects on glycemia were attributable solely to weight loss is unclear, and
         <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">
          semaglutide
         </a>
         must be continued indefinitely to prevent body weight regain [
         <a href="#rid48">
          48
         </a>
         ]. Longer term studies are needed to establish the duration of both the weight loss and glycemic effects of semaglutide. In addition, the cost of semaglutide relative to that of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         should be considered.
        </p>
        <p class="headingAnchor" id="H2882042769">
         <span class="h2">
          Drugs not recommended for prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Longer follow-up studies (at least 10 years) of pharmacologic therapy, as has been done with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         in the DPP, with demonstration of reduced morbidity and mortality, are needed before other drugs can be recommended for the majority of patients at high risk for diabetes.
        </p>
        <p>
         We do not administer the following drugs for prevention of diabetes in patients with IGT and/or IFG, given the modest benefit in reducing the incidence of diabetes in the short term, the side effects, and/or the absence of proven cardiovascular benefit:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insulin [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          Liraglutide
         </a>
         [
         <a href="#rid41">
          41,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          Pioglitazone
         </a>
         [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          Rosiglitazone
         </a>
         [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10179" href="/z/d/drug information/10179.html" rel="external">
          Orlistat
         </a>
         [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha-glucosidase inhibitors (eg,
         <a class="drug drug_general" data-topicid="9219" href="/z/d/drug information/9219.html" rel="external">
          acarbose
         </a>
         , voglibose) [
         <a href="#rid56">
          56-59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitamin D [
         <a href="#rid60">
          60,61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">
          "Vitamin D and extraskeletal health", section on 'Type 2 diabetes, obesity, and metabolic syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium-glucose co-transporter 2 (SGLT2) inhibitors [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9927" href="/z/d/drug information/9927.html" rel="external">
          Nateglinide
         </a>
         [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Estrogen [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-hypertension medications (angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]) [
         <a href="#rid66">
          66,67
         </a>
         ]. However, ACE inhibitors and ARBs are appropriate agents for initial treatment of hypertension in patients at high risk for diabetes. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In addition to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , thiazolidinediones, alpha-glucosidase inhibitors,
         <a class="drug drug_general" data-topicid="10179" href="/z/d/drug information/10179.html" rel="external">
          orlistat
         </a>
         , and
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         have demonstrated preventive efficacy [
         <a href="#rid5">
          5,41,44,50,68
         </a>
         ]. Although these drugs delay the onset of diagnosis of diabetes and therefore reduce the length of exposure of hyperglycemia, the benefit or harm of the intervention, independent of the effect on hyperglycemia, must be considered. As an example, thiazolidinediones are limited by adverse effects (fluid retention, weight gain, heart failure, bone loss, possibly myocardial infarction [MI] for
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          rosiglitazone
         </a>
         , and possibly bladder cancer for
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          pioglitazone
         </a>
         ) and alpha-glucosidase inhibitors by gastrointestinal side effects and poor long-term compliance. The use of thiazolidinediones, in particular, for the prevention of diabetes may cause more net harm than benefit. In contrast, metformin is relatively inexpensive and safe and is especially effective in younger, heavier individuals [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Safety'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1787.html" rel="external">
          "Alpha-glucosidase inhibitors for treatment of diabetes mellitus", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         Although
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         has been shown to decrease cardiovascular outcomes in patients with type 2 diabetes, the impact of liraglutide treatment on cardiovascular outcomes in patients without established diabetes is unknown. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12588522">
         <span class="h1">
          BARIATRIC SURGERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical treatment of obesity in people with diabetes results in a large degree of sustained weight loss and, in parallel, large improvements in glycemia (see
         <a class="medical medical_review" href="/z/d/html/586.html" rel="external">
          "Bariatric surgery for management of obesity: Indications and preoperative preparation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Bariatric (metabolic) surgery'
         </a>
         ). There are few data evaluating the ability of bariatric surgery to prevent diabetes in individuals with obesity. In a nonrandomized trial from Sweden comparing bariatric surgery with usual care, 2010 individuals chose to undergo surgery for obesity (gastric banding, gastroplasty, or gastric bypass) while 2037 chose conventional treatment [
         <a href="#rid69">
          69
         </a>
         ]. After 15 years, type 2 diabetes developed in 110 and 392 patients in the surgery and control groups, respectively (incidence rates of 6.8 and 28.4 cases per 1000 person-years) [
         <a href="#rid70">
          70
         </a>
         ]. Baseline body mass index (BMI) did not influence the effect of bariatric surgery on the incidence of diabetes. The study had several limitations, including a lack of randomization and a high loss to follow-up rate (36 percent at 15 years). In addition, 31 percent of patients had not yet been followed for 15 years. Thus, the unadjusted 15-year participation rate was only 32.9 percent. The potential mechanisms for improvement in insulin resistance and beta cell function after bariatric surgery are uncertain and include a reduction in caloric intake, weight loss, and anatomic changes as a result of malabsorptive procedures. Additional studies are warranted.
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          GUIDELINES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          American Diabetes Association (ADA)
         </strong>
         – The ADA recommends lifestyle modification as the primary intervention in subjects with impaired glucose tolerance (IGT), impaired fasting glucose (IFG), or an A1C of 5.7 to 6.4 percent (39 to 46 mmol/mol) [
         <a href="#rid3">
          3,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific goals include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Modest weight loss (≥7 percent of body weight)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate-intensity exercise (≥150 minutes per week)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Smoking cessation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because of its effectiveness, low cost, and long-term safety, the ADA recommends consideration of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for prevention of diabetes in individuals at highest risk for developing diabetes, such as those with IGT, IFG, or an A1C of ≥6 percent, particularly for those who benefited most from metformin during the Diabetes Prevention Program (DPP; &lt;60 years of age, body mass index [BMI] ≥35 kg/m
         <sup>
          2
         </sup>
         , women with a history of gestational diabetes)  (
         <a class="graphic graphic_table graphicRef67073" href="/z/d/graphic/67073.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. In addition, assessment for and treatment of modifiable cardiovascular risk factors, such as hypertension and dyslipidemia, is important to reduce cardiometabolic risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients treated with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         require at least annual monitoring (A1C or fasting glucose) for the development of diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ADA recommendations for diabetes screening are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus", section on 'Screening recommendations by expert groups'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Community Preventive Services Task Force
         </strong>
         – The task force recommends combined diet and physical activity programs for individuals at increased risk for type 2 diabetes [
         <a href="#rid71">
          71
         </a>
         ]. An economic evaluation of 28 studies showed that such lifestyle programs were cost effective [
         <a href="#rid72">
          72
         </a>
         ]. Costs were lower when lifestyle modification programs were delivered to groups in community or primary care settings. The use of pharmacologic therapy was not addressed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          National Institute for Health and Care Excellence (NICE)
         </strong>
         – In the United Kingdom, NICE guidelines suggest
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for patients with elevated fasting plasma glucose (FPG; 100 to 125 mg/dL [5.6 to 6.9 mmol/L]) or A1C (6 to 6.5 percent [42 to 47 mmol/mol]) who are unable to participate in lifestyle interventions or in whom FPG or A1C values deteriorate despite participation in a lifestyle intervention program [
         <a href="#rid73">
          73
         </a>
         ]. They also suggest
         <a class="drug drug_general" data-topicid="10179" href="/z/d/drug information/10179.html" rel="external">
          orlistat
         </a>
         for those with a BMI &gt;28 kg/m
         <sup>
          2
         </sup>
         whose FPG or A1C show deterioration, as part of an overall strategy to reduce weight. (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1133749340">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122142.html" rel="external">
          "Society guideline links: Prevention of type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">
          "Society guideline links: Diabetes mellitus in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111575.html" rel="external">
          "Society guideline links: Diabetes mellitus in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15402.html" rel="external">
          "Patient education: Type 2 diabetes (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16892.html" rel="external">
          "Patient education: Lowering your risk of prediabetes and type 2 diabetes (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1743.html" rel="external">
          "Patient education: Type 2 diabetes: Overview (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H364465">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of diabetes prevention
         </strong>
         – The goals of diabetes prevention include preventing or delaying the onset of diabetes, preserving beta cell function, and preventing or delaying microvascular and cardiovascular complications. (See
         <a class="local">
          'Goals of diabetes prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identify individuals for preventive measures
         </strong>
         – In order to identify individuals who are appropriate candidates for preventive interventions, we measure glycated hemoglobin (A1C) or fasting plasma glucose (FPG) in adults ≥35 years of age, in women with a history of gestational diabetes, and in adults of any age with body mass index (BMI) &gt;25 kg/m
         <sup>
          2
         </sup>
         who have one or more additional risk factors for diabetes (eg, family history of diabetes mellitus in a first-degree relative, sedentary lifestyle, hypertension, dyslipidemia)  (
         <a class="graphic graphic_table graphicRef122948" href="/z/d/graphic/122948.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lifestyle intervention
         </strong>
         – Lifestyle modification (predominantly exercise and weight loss) successfully decreases the development of diabetes  (
         <a class="graphic graphic_table graphicRef113534" href="/z/d/graphic/113534.html" rel="external">
          table 5
         </a>
         ). Thus, we promote lifestyle changes (healthy diet and regular exercise) to all patients. Regular reinforcement of these benefits is important for successful compliance. Patients should also be encouraged to stop smoking. Patients who are at high risk  (
         <a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">
          table 3
         </a>
         ) should be followed closely, with repeat examination and measurements of fasting blood glucose or A1C on an annual basis. (See
         <a class="local">
          'Our approach'
         </a>
         above and
         <a class="local">
          'Lifestyle modification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacologic therapy
         </strong>
         – For selected patients (age &lt;60 years and/or BMI ≥35 kg/m
         <sup>
          2
         </sup>
         , women with a history of gestational diabetes) with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or A1C of 5.7 to 6.4 percent, in whom lifestyle interventions fail to improve glycemic indices, we suggest
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for diabetes prevention  (
         <a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef67073" href="/z/d/graphic/67073.html" rel="external">
          table 4
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). For individuals with overweight or obesity and prediabetes,
         <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">
          semaglutide
         </a>
         used for obesity pharmacotherapy may help delay or prevent the onset of overt diabetes. (See
         <a class="local">
          'Our approach'
         </a>
         above and
         <a class="local">
          'Pharmacologic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients treated with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         require at least annual monitoring (A1C or fasting glucose). (See
         <a class="local">
          'Metformin'
         </a>
         above and
         <a class="local">
          'Guidelines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2061441773">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Brancati FL, Kao WH, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000; 283:2253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udler MS, McCarthy MI, Florez JC, Mahajan A. Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine. Endocr Rev 2019; 40:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillett M, Royle P, Snaith A, et al. Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess 2012; 16:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selph S, Dana T, Blazina I, et al. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015; 162:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balk EM, Earley A, Raman G, et al. Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med 2015; 163:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmingsen B, Gimenez-Perez G, Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev 2017; 12:CD003054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379:2243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014; 2:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013; 347:f5577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan DM, Bennett PH, Crandall JP, et al. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia 2019; 62:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uusitupa M, Khan TA, Viguiliouk E, et al. Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis. Nutrients 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25:2165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sussman JB, Kent DM, Nelson JP, Hayward RA. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015; 350:h454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29:2102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; 93:4774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care 2015; 38:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015; 3:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012; 35:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch J, Helmrich SP, Lakka TA, et al. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Arch Intern Med 1996; 156:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu FB, Sigal RJ, Rich-Edwards JW, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA 1999; 282:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991; 34:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu G, Lindström J, Valle TT, et al. Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med 2004; 164:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Chen Z, Pan L, et al. Effect of Moderate and Vigorous Aerobic Exercise on Incident Diabetes in Adults With Obesity: A 10-Year Follow-up of a Randomized Clinical Trial. JAMA Intern Med 2023; 183:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo M, Yu C, Del Pozo Cruz B, et al. Accelerometer-measured intensity-specific physical activity, genetic risk and incident type 2 diabetes: a prospective cohort study. Br J Sports Med 2023; 57:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AD, Crippa A, Woodcock J, Brage S. Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies. Diabetologia 2016; 59:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grøntved A, Rimm EB, Willett WC, et al. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med 2012; 172:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation 2016; 133:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salas-Salvadó J, Bulló M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011; 34:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salas-Salvadó J, Bulló M, Estruch R, et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 2014; 160:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomfield HE, Koeller E, Greer N, et al. Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 165:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018; 378:e34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinker LF, Bonds DE, Margolis KL, et al. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. Arch Intern Med 2008; 168:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2017; 5:CD012204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen KS, Chi Y, Metzendorf MI, et al. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2019; 12:CD008558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan DM, Berkwits M. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med 2007; 146:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perreault L, Davies M, Frias JP, et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care 2022; 45:2396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021; 325:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389:1399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care 2011; 34:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program. Diabetes Care 2006; 29:2095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moelands SV, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev 2018; 12:CD005061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med 2019; 381:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pittas AG, Kawahara T, Jorde R, et al. Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Ann Intern Med 2023; 176:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori Y, Duru OK, Tuttle KR, et al. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab 2022; 108:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NAVIGATOR Study Group, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004; 47:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DREAM Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005; 28:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pronk NP, Remington PL, Community Preventive Services Task Force. Combined Diet and Physical Activity Promotion Programs for Prevention of Diabetes: Community Preventive Services Task Force Recommendation Statement. Ann Intern Med 2015; 163:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li R, Qu S, Zhang P, et al. Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med 2015; 163:452.
          </a>
         </li>
         <li class="breakAll">
          NICE public health guidance. http://publications.nice.org.uk/preventing-type-2-diabetes-risk-identification-and-interventions-for-individuals-at-high-risk-ph38/recommendations#recommendation-3-risk-identification-stage-1 (Accessed on May 02, 2013).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1774 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807384" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31322649" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38078581" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22935084" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25867111" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26167912" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29205264" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17098085" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19878986" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22683134" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502303" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24731674" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24473061" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31270584" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31683759" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11333990" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11832527" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12453955" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Diabetes Prevention Program (DPP): description of lifestyle intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25697494" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16936160" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of weight loss with lifestyle intervention on risk of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18826999" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25336746" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26377054" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22442395" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2052059" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8651839" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10535433" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1778354" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmöfeasibility study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111376" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36716009" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of Moderate and Vigorous Aerobic Exercise on Incident Diabetes in Adults With Obesity: A 10-Year Follow-up of a Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37277158" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Accelerometer-measured intensity-specific physical activity, genetic risk and incident type 2 diabetes: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27747395" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22868691" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A prospective study of weight training and risk of type 2 diabetes mellitus in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26746178" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20929998" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24573661" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27428849" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23432189" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Primary prevention of cardiovascular disease with a Mediterranean diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29897866" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18663162" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28489279" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31794067" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17371892" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17237299" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17327355" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Impaired fasting glucose and impaired glucose tolerance: implications for care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12663559" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35724304" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33755728" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22686416" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Basal insulin and cardiovascular and other outcomes in dysglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28237263" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21428766" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pioglitazone for diabetes prevention in impaired glucose tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16997664" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21515846" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Incidence of diabetes following ramipril or rosiglitazone withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14693982" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10809036" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12086760" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16936159" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19395079" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30592787" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31173679" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Vitamin D Supplementation and Prevention of Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36745886" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36217306" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20228402" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effect of nateglinide on the incidence of diabetes and cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12513038" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15252707" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16980380" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effect of ramipril on the incidence of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20228403" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of valsartan on the incidence of diabetes and cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15735219" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A systematic review of drug therapy to delay or prevent type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15616203" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22913680" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26168073" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Combined Diet and Physical Activity Promotion Programs for Prevention of Diabetes: Community Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26167962" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
